This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Advanced Cancer
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a dose-escalation Phase 1 study designed to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose, and the safety profile of CDX-0158 in patients with KIT-positive advanced solid malignancies refractory to standard therapy or for which no standard therapy exists.

Provided treatments

  • Biological: CDX-0158 (formerly known as KTN-0158)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02642016. The sponsor of the trial is Celldex Therapeutics and it is looking for 28 volunteers for the current phase.
Official trial title:
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.